New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 1, 2013
14:52 EDTSHPG, BIIB, BMYBiogen, Shire among targets considered by Bristol-Myers, WSJ says
Bristol-Myers Squibb (BMY) has recently studied a possible acquisition of Biogen Idec (BIIB) and previously engaged advisers to look into the acquisition of Shire (SHPG), according to The Wall Street Journal, citing people familiar with the matters. Shares of both smaller companies rose following the initial report. In afternoon trading, Biogen advanced 0.7% to $167.50, while Shire rose 1.7% to $95.28. Reference Link
News For BIIB;SHPG;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 27, 2015
08:19 EDTBMYBristol-Myers announces ALLY-1 trial met primary endpoints
Subscribe for More Information
08:15 EDTBIIBBiogen weakness creates buying opportunity, says RBC Capital
Subscribe for More Information
06:19 EDTBMYPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
15:16 EDTBIIBBiogen sell off a buying opportunity, Barron's says
Biogen is down about 6% on the session after reporting Q1 results that missed expectations. The pullback represents a buying opportunity as the company's drug pipeline should fuel strong growth, Barron's says. Reference Link
09:28 EDTBIIBPiper says Biogen has 'long way to go' before being top pick again
Subscribe for More Information
09:20 EDTBIIBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: eHealth (EHTH), up 24.7%... Starbucks (SBUX), up 4.2%... Microsoft (MSFT), up 5.2%... Google (GOOG, GOOGL), up 3.2% and up 3.7%, respectively... Amazon (AMZN), up 12% after reporting quarterly results and announcing shopping app for Apple Watch... Gigamon (GIMO), up 16.5%... Juniper Networks (JNPR), up 6.6%. ALSO HIGHER: Molycorp (MCP), up 10.2% following a Bloomberg report that China's export tax decision may boost rare earth demand... Mattel (MAT), up 4.4% after being upgraded to Buy from Neutral at Goldman... Innocoll (INNL), up 13.1% after 3.3M share Secondary priced at $9.00... Cytosorbents (CTSO), up 9.7% after CEO comments on CytoSorb in letter to shareholders. DOWN AFTER EARNINGS: Biogen (BIIB), down 4.7%... Altera (ALTR), down 1.7%... Pandora (P), down 4%... ResMed (RMD), down 8.7%... Xerox (XRX), down 4.7%... HomeAway (AWAY), down 3.6% after reporting quarterly results and departure of officers. ALSO LOWER: Ubiquiti (UBNT), down 14.4% following CFO resignation and preliminary third quarter results... 3D Systems (DDD), down 10.4% after reporting preliminary first quarter results... StemCells (STEM), down 23.2% after filing to sell common stock... Aerie Pharmaceuticals (AERI), down 54.7% after Rhopressa Phase 3 trial did not meet primary endpoint.
08:09 EDTBMYBristol-Myers May weekly volatility elevated into Q1 and outlook
Bristol-Myers May weekly call option implied volatility is at 27, May is at 21, June is at 22, September is at 22; compared to its 26-week average of 22 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 28.
07:47 EDTBMYBristol-Myers receives positive CHMP opinion in EU for Opdivo
Subscribe for More Information
07:40 EDTBIIBForward Pharma price target raised to $53 from $43 at Leerink
Subscribe for More Information
07:02 EDTBIIBBiogen reports Q1 Tecfidera revenue $825M
Total multiple sclerosis product sales were $2.1 billion compared to $1.7 billion in the same quarter last year. Interferon revenues, including Avonex and Plegridy were $755M in Q1. Tysabri revenues were $463M. Net revenues relating to Rituxan and Gazyva were $331M. Elocate revenues were $54M, Alprolix revenues were $43M.
07:01 EDTBIIBBiogen reports Q1 adjusted EPS $3.82, consensus $3.91
Subscribe for More Information
April 23, 2015
15:07 EDTBIIBBiogen technical comments before earnings
Subscribe for More Information
15:01 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information
09:20 EDTSHPGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
April 22, 2015
07:07 EDTSHPG, BMYEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 21, 2015
10:00 EDTBMYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:52 EDTBIIBBiogen April weekly volatility elevated into Q1 and outlook
Biogen April weekly call option implied volatility is at 74, May is at 35, June is at 32, July is at 31; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 24.
07:31 EDTBIIBBiogen says data presented from ATTAIN study demonstrate efficacy of Plegridy
Subscribe for More Information
06:44 EDTBMYBristol-Myers upgraded on early Opdivo success at Morgan Stanley
As previously reported, Morgan Stanley upgraded Bristol-Myers to Overweight from Equal Weight. The firm raised estimates above consensus and increased its price target on the stock to $80 from $60 following confirmation of Opdivo's survival benefits in lung cancer. Morgan Stanley expects Opdivo to be one of the top three pharma-bio launches over the next several years and notes Bristol is ahead of the competition in immuno-oncology combination drug development.
06:15 EDTBMYBristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use